The first of two protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to lower low-density lipoprotein cholesterol (LDL-C) made its way with favor through the FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), setting the stage for the second – maybe more fraught – PCSK9, which EMDAC will evaluate today.